BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Calabrò D, Argalia G, Ambrosini V. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.Diagnostics (Basel). 2020;10. [PMID: 33297381 DOI: 10.3390/diagnostics10121059] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Opalińska M, Sowa-staszczak A, Al Maraih I, Gilis-januszewska A, Hubalewska-dydejczyk A. Peptide receptor radionuclide therapy as a tool for the treatment of severe hypoglycemia in patients with primary inoperable insulinoma. Bio-Algorithms and Med-Systems 2022;17:221-6. [DOI: 10.1515/bams-2021-0138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Segaran N, Devine C, Wang M, Ganeshan D. Current update on imaging for pancreatic neuroendocrine neoplasms. World J Clin Oncol 2021; 12(10): 897-911 [PMID: 34733612 DOI: 10.5306/wjco.v12.i10.897] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Popa O, Taban SM, Pantea S, Plopeanu AD, Barna RA, Cornianu M, Pascu AA, Dema ALC. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5. Exp Ther Med 2021;22:1179. [PMID: 34475969 DOI: 10.3892/etm.2021.10613] [Cited by in F6Publishing: 10] [Reference Citation Analysis]